Evidence map›Paper›PMID 27428434›Full record

ArticleEBioMedicine2016

Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants.

Nina Lin, Oscar A Gonzalez, Ludy Registre, Carlos Becerril, Behzad Etemad, Hong Lu, Xueling Wu, Shahin Lockman, Myron Essex, Sikhulile Moyo and 2 more

Abstract read
In one paragraph

Article in EBioMedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nina LinSection of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, MA, United States.
Oscar A GonzalezSection of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, MA, United States.
Ludy RegistreSection of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, MA, United States.
Carlos BecerrilDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, United States.
Behzad EtemadSection of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, MA, United States.
Hong LuAaron Diamond AIDS Research Center, New York, NY, United States.
Xueling WuAaron Diamond AIDS Research Center, New York, NY, United States.
Shahin LockmanDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, United States; Harvard School of Public Health, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.
Myron EssexHarvard School of Public Health, Boston, MA, United States; Botswana Harvard AIDS Institute, Gaborone, Botswana.
Sikhulile MoyoBotswana Harvard AIDS Institute, Gaborone, Botswana.
Daniel R KuritzkesDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.
Manish SagarSection of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, MA, United States. Electronic address: msagar@bu.edu.

Funding

Training in HIV Genomics, Treatment, and Cure Research in BotswanaD43TW009610 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI SHAHIN LOCKMAN, Joseph Moeketsi Makhema · 2013 to 2026
$4.4M
CD1a Vaginal Dendritic Cells and HIV-1 Acquisition in the Female Genital TractR01AI122209 · NIAID · BOSTON MEDICAL CENTER · PI SAGAR, MANISH · 2015 to 2019
$2.2M
FIC NIH HHS D43 TW009610NIAID NIH HHS R01 AI122209
6 · The paper itself

Abstract

Although both C-C chemokine receptor 5 (CCR5)- and CXC chemokine receptor 4 (CXCR4)-using HIV-1 strains cause AIDS, the emergence of CXCR4-utilizing variants is associated with an accelerated decline in CD4+ T cells. It remains uncertain if CXCR4-using viruses hasten disease or if these variants only emerge after profound immunological damage. We show that exclusively CXCR4- as compared to cocirculating CCR5-utilizing variants are less sensitive to neutralization by both contemporaneous autologous plasma and plasma pools from individuals that harbor only CCR5-using HIV-1. The CXCR4-utilizing variants, however, do not have a global antigenic change because they remain equivalently susceptible to antibodies that do not target coreceptor binding domains. Studies with envelope V3 loop directed antibodies and chimeric envelopes suggest that the neutralization susceptibility differences are potentially influenced by the V3 loop. In vitro passage of a neutralization sensitive CCR5-using virus in the presence of autologous plasma and activated CD4+ T cells led to the emergence of a CXCR4-utilizing virus in 1 of 3 cases. These results suggest that in some but not necessarily all HIV-1 infected individuals humoral immune pressure against the autologous virus selects for CXCR4-using variants, which potentially accelerates disease progression. Our observations have implications for using antibodies for HIV-1 immune therapy.

Indexed as

Immunity, HumoralCD4 Lymphocyte CountHIV-1HIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHost-Pathogen InteractionsHumansNeutralization TestsProtein BindingReceptors, CXCR4Receptors, HIVViral LoadViral TropismVirus ReplicationHIV AntibodiesHIV Envelope Protein gp120Receptors, CXCR4Receptors, HIVCo-receptorEnvelopeEvolutionHIVNeutralizationResistanceTropism

Identifiers

PMID27428434
PMCPMC4919596

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.